B
Beijing Xinyi Biotechnology
Targeting One develops in-vitro diagnostic products
About Beijing Xinyi Biotechnology
Founded in 2015 by Wenjun Yang, Beijing Xinyi Biotechnology, which operates as TargetingOne, is a high-tech enterprise situated in Beijing's Zhongguancun Science and Technology Park. The firm concentrates on the independent development of molecular diagnostic technology, particularly digital PCR (dPCR), and its application to major diseases. TargetingOne has experienced rapid development, applying for over 200 patents and receiving more than 150.
The company's business revolves around the manufacturing of micro-droplet digital PCR instruments and in-vitro diagnostic reagents. Its product portfolio includes a range of PCR instruments, reagents, and sample extraction tools. These products provide a technical method for the research and diagnosis of tumors, genetic diseases, and infectious diseases. TargetingOne's clients are in the life sciences, precision medicine, drug development, and health management sectors. The business model is centered on developing and selling these advanced molecular diagnostic systems and reagents.
TargetingOne offers a suite of products based on its proprietary dPCR technology. This includes the D30 and D50 Automatic Digital PCR Systems, which are designed for high-throughput, automated analysis. The company also produces various detection kits for specific applications, such as the Human EGFR Gene Mutation Detection Kit for lung cancer liquid biopsies and a Hepatitis B DNA Quantitative Detection Digital PCR Reagent. A key feature of their dPCR technology is its high sensitivity and accuracy, which allows for absolute quantification of nucleic acids without reliance on standard curves, a limitation of traditional qPCR methods. This makes it particularly effective for detecting rare mutations and pathogens in low concentrations. The company's dPCR testing kit for SARS-CoV-2 was the first of its kind to receive a Class III medical device registration certificate from China's NMPA.
Significant milestones include raising a total of $23.2 million over three funding rounds, with a notable Series B round in January 2021 led by Lilly Asia Ventures. The latest funding was a Series B round on February 25, 2024, led by Jiuzhi Capital. The company has received numerous accolades, including the Gold Award of China In Vitro Diagnostic Excellent Innovation Product for two consecutive years. Its products have also gained international recognition, with CE market approval in the European Union for its novel coronavirus nucleic acid testing products.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Apr 2024 | $14M | $103M | Shunxi Private Equity Fund Management · Beijing Medical Fund · Beijing Medical and Health Industry Investment Fund | ↗ |
| SERIES B✓Equity / VC | Feb 2024 | $14M | $103M | Jiuzhi Capital · Lilly Asia Ventures · Shengdi Investment | ↗ |
Growth signals
Latest recorded traffic for Beijing Xinyi Biotechnology is 190 monthly website visits, up 35.7% over the last three months. Beijing Xinyi Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
| Shenzhen, China | Operational | — | — | — | |
Macula Vision SystemsAI-powered computational microscopy for clinical sample analysis |
Tucson, United States | Operational | |||
MDHC Life TechnologiesA platform for automated lab equipment and consumables, offering minimally invasive surgical solutions |
China | Operational | |||
| Hefei, China | Operational | ||||
HandyemMedical Equipment Manufacturing |
Quebec City, Canada | Operational | |||
Micronbrane MedicalBiotechnology company based in Taiwan |
Taichung, Taiwan | Operational | |||
BiosensPoint-of-care biosensors for rapid medical diagnostics |
São Leopoldo, Brazil | Operational | |||
Autonomous Medical DevicesCreating medical devices that automate complicated laboratory assays |
Los Angeles, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Xinyi Biotechnology in the Haidian ecosystem
The Beijing Xinyi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Lilly Asia Ventures
Hillhouse Capital
China Growth Capital
Jiuzhi Capital
Shengdi Investment
Series B and later3 investors entered at this stage
- SMShunxi Private Equity Fund Management
- BFBeijing Medical Fund
- BFBeijing Medical and Health Industry Investment Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Xinyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Xinyi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








